214 related articles for article (PubMed ID: 24351780)
1. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
3. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
4. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
5. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
6. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
7. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
Samis J; Lee P; Zimmerman D; Arceci RJ; Suttorp M; Hijiya N
Pediatr Blood Cancer; 2016 Aug; 63(8):1332-8. PubMed ID: 27100618
[TBL] [Abstract][Full Text] [Related]
8. Third-line therapy for chronic myeloid leukemia: current status and future directions.
Cortes J; Lang F
J Hematol Oncol; 2021 Mar; 14(1):44. PubMed ID: 33736651
[TBL] [Abstract][Full Text] [Related]
9. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
10. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
11. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
12. Kinase inhibitors in chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
[TBL] [Abstract][Full Text] [Related]
13. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
14. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
16. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
18. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
19. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
20. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Kimura S
Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
